9/9 These results suggest that integrating genomic and transcriptomic profiling can help: 1) identify patients who may not respond to PD-(L)1 monotherapy with more accuracy & 2) redirect them to the most appropriate immunotherapy approach. Link: https:
RT @dmarinelli93: Our work out in @CCR_AACR: NRF2-driven transcription is found in ~50% of NSCLC and is associated with worse outcomes wit…
RT @dmarinelli93: Our work out in @CCR_AACR: NRF2-driven transcription is found in ~50% of NSCLC and is associated with worse outcomes wit…
RT @dmarinelli93: Our work out in @CCR_AACR: NRF2-driven transcription is found in ~50% of NSCLC and is associated with worse outcomes wit…